

ANDREW M. CUOMO

Governor

ANN MARIE T. SULLIVAN, M.D.

Commissioner

THOMAS E. SMITH, MD
Chief Medical Officer

## **MEMORANDUM**

**TO:** NYS Article 31 Mental Health Provider Agencies

NYS Article 28 Hospital Psychiatry Chiefs

OMH-Operated Psychiatric Center Executive Directors, Clinical Directors, Chief

Nursing Officers, Pharmacists

**FROM:** Dr. Thomas Smith, Chief Medical Officer, OMH

**DATE:** March 21, 2020

**SUBJECT:** Clozapine and blood test monitoring

I have communicated with both the FDA and Clozapine REMS and can confirm that prescribers and pharmacies have discretion to order and dispense clozapine without an absolute neutrophil count reported within the specified timeframes. The following is posted on the Clozapine REMS website (<a href="https://www.clozapinerems.com/CpmgClozapineUI/home.u#">https://www.clozapinerems.com/CpmgClozapineUI/home.u#</a>):

## \*\*\*Important Program Update (as of 01/23/2020)\*\*\*

## **ANC Current Lab Requirements**

Absolute Neutrophil Count not current (i.e., within 7, 15, or 31 days of the lab draw date) based on the patient's monitoring frequency (MF) will not prevent a patient from receiving clozapine from the pharmacy.

Although 'ANC not current' will not prevent a patient from receiving clozapine from the pharmacy, pharmacies are encouraged to submit the ANC to the Clozapine REMS Program when the pharmacist is made aware of a more current ANC than the most recent lab value reported in the PDA response...

CC:

OMH Executive Team
OMH Senior Staff
Marc Manseau, MD, OASAS
Theodore Kastner, MD, OPWDD
Alison Burke, GNYHA
Victoria Aufiero, HANYS
OMH COVID-19 Communication Team